01—Abstract
Summary
Summary of the 10-K filed February 11, 2025. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported its eighth consecutive year of annual profitability for 2024, with net income of $521.3 milliona, or $1.76 per diluted share, compared with $207.8 million, or $0.65 per share, in 2023.
Total revenues rose to $2,168.7 millionb from $1,830.2 million, driven by net product revenues of $1,809.4 million, almost entirely from CABOMETYX, and license revenues of $349.2 million, which include a $150.0 million commercial milestone from Ipsen. Fiscal 2024 was a 53-week year. The company ended the year with $1.7 billion in cash, cash equivalents and marketable securities and repurchased $652.0 million of its common stock during 2024 under two programs.
The company's growth depends on CABOMETYX, which the filing says accounts for the majority of revenues. The filing notes that the CABOMETYX plus nivolumab first-line RCC combination drove the 8.2%c increase in CABOMETYX units sold. Pipeline catalysts include the pending FDA decision on CABINET (pNET/epNET) with a PDUFA date of April 3, 2025, and the lead investigational asset zanzalintinib, with several pivotal trials ongoing.
The company also reported that COSMIC-313 did not show an overall survival benefit and will not be pursued for marketing authorization. CONTACT-02 showed a non-significant overall survival trend. The filing also flags material risks.
Generic challengers have filed ANDAs against CABOMETYX: MSN, Teva, Cipla and Sun. Settlements with Teva and Cipla allow generic entry beginning January 1, 2031, and a court judgment sets MSN's earliest effective approval date at January 15, 2030.
The 340B Program Integrity Initiative is under challenge, and the IRA drug-pricing provisions create additional uncertainty. Management projects higher 2025 net product revenues, lower license revenues and higher R&D expense.
02—Key points
Key Highlights
- Net income of $521.3 million ($1.76 diluted EPS) in 2024, up from $207.8 million ($0.65) in 2023; the eighth consecutive year of annual profitability.
- Total revenues of $2,168.7 million, up from $1,830.2 million; net product revenues of $1,809.4 million, with CABOMETYX at $1,798.2 million and COMETRIQ at $11.2 million.
- License revenues rose to $349.2 million, including a $150.0 million commercial milestone from Ipsen tied to $600 million in cumulative cabozantinib net sales.
- Pending FDA decision on the CABOMETYX sNDA for previously treated pNET/epNET, with a PDUFA target action date of April 3, 2025.
- Generic entry risk: MSN, Teva, Cipla and Sun have filed ANDAs; Teva and Cipla settlements permit generic launch from January 1, 2031, and a court judgment sets MSN's earliest effective approval at January 15, 2030.
- Cash, cash equivalents and marketable securities of $1.7 billion at year-end; $652.0 million of stock repurchases paid in 2024 and $294.4 million remaining under the 2025-expiring program.
- Pipeline setbacks and reprioritization: COSMIC-313 showed no overall survival benefit and will not be pursued for marketing authorization; XB002 development was discontinued; the 2024 restructuring cost $33.7 million.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2025, Exelixis kept $0.24.
- Revenue$2.17B100.0%
- Cost of revenue−$76.2M3.5%
- Gross profit$2.09B96.5%
- Operating costs−$1.49B68.6%
- Operating income$604.6M27.9%
- Interest, other & tax−$83.3M3.8%
- Net income$521.3M24.0%
Where FY2025 revenue went
$2.17B- R&D: $910.4M, 42% of revenue
- Net income: $521.3M, 24% of revenue
- SG&A: $492.1M, 23% of revenue
- Cost of revenue: $76.2M, 3.5% of revenue
- Other operating costs: $85.3M, 3.9% of revenue
- Interest, other & tax: $83.3M, 3.8% of revenue
Kept 24% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2025filed February 11, 2025Financial Statements
| Revenue | $2.17B |
| Cost of Revenue | $76.22M |
| Gross Profit | $2.09B |
| R&D Expenses | $910.41M |
| SG&A Expenses | $492.13M |
| Operating Expenses | $1.56B |
| Operating Income | $604.62M |
| Net Income | $521.30M |
| EPS (Basic) | $1.80 |
| EPS (Diluted) | $1.76 |
| Shares Outstanding (Basic) | 290.03M |
| Shares Outstanding (Diluted) | 296.13M |
05—Questions
Frequently Asked Questions
How dependent is Exelixis on CABOMETYX?
Heavily. The filing says sales related to cabozantinib account for the majority of revenues, and CABOMETYX net product revenues were $1,798.2 million in 2024 versus $1,809.4 million total net product revenues. Management states that the company's ability to generate cash flow depends on continued commercial success of CABOMETYX.
When could generic competition to CABOMETYX begin?
The filing describes several paths. Under settlement agreements, Teva and Cipla may launch generics beginning January 1, 2031. In MSN litigation, the Delaware District Court entered judgment that any FDA approval of MSN's ANDA cannot be effective before January 15, 2030. Sun's ANDA litigation and an MSN paragraph IV filing in February 2025 remain pending.
What is the outlook for 2025 revenue and expenses?
Management projects net product revenues may increase in 2025 versus 2024, while license revenues may decrease due to fewer expected milestones. Research and development expenses are projected to increase, primarily from license costs and clinical trials for zanzalintinib, XL309, XL495 and XB010. Selling, general and administrative expenses may also rise, reflecting the Branded Prescription Drug Fee and marketing for the anticipated pNET/epNET launch.
What are the key near-term pipeline catalysts?
The filing cites the FDA PDUFA target date of April 3, 2025 for CABOMETYX in previously treated pNET/epNET, initial clinical data from STELLAR-002 expected in the first half of 2025, and preliminary STELLAR-303 results expected in the second half of 2025 subject to event rates. STELLAR-304 primary PFS is expected in the second half of 2025, and STELLAR-311 is planned to start in the first half of 2025.
How much capital has been returned to shareholders?
The filing reports that $450.0 million was repurchased under a January 2024 program, completed by June 30, 2024, and $205.6 million under an August 2024 program authorizing up to $500 million through 2025. About $294.4 million remained available as of December 31, 2024. Total cash paid for repurchases in 2024 was $652.0 million, per the cash flow statement.
06—Continue